New advances in chronic hepatitis B

Current Opinion in Gastroenterology

Volumn 28, Issue 3, 2012, Pages 193-197

  Tujios, Shannan R ^a   Lee, William M ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

antiviral therapy; chronic hepatitis B; chronic liver disease; nucleoside analogs

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; RECOMBINANT ALPHA2A INTERFERON; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DISEASE COURSE; DRUG POTENCY; GENETIC RESISTANCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; PREGNANCY; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; VACCINATION;

ADENINE; ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; GUIDELINES AS TOPIC; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS D; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 84859904523     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835297ef     Document Type: Review

References (36)

1. Wiersma S. The global burden of disease of viral hepatitis. Viral Hepat 2011; 19:9-10.
2. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154:319-328.
3. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51:729-733.
4. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18:1-16.
5. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26:628-638.
6. Chen YC, Jeng WJ, Chu CM, et al. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012; 10:297-302.
7. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 55:68-76.
8. Hadziyannis S. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011; 55:183-191.
9. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011; 52:1294-1306.
10. Wong WW, Woo G, Heathcote JE, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011; 31:1179-1190.
11. Younossi ZM, Stepanova M. Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology 2011; 54:1167-1178.
12. CDC. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2011; 50:1709-1711.
13. Chan HL, Thompson A, Marinot-Peignoux M, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011-a core group report. J Hepatol 2011; 55:1121-1131.
14. Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2011. doi 10.1136/gutjnl-2011-301096.
15. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011; 31 (Suppl 1):122-128.
16. Liaw YF. Clinical utility of hepatitis B surface antigen quantification in patients with chronic hepatitis B: a review. Hepatology 2011; 54:E1-E9.
17. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
18. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142:513-520.e1.
19. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012. doi: 10.1016/j.jhep.2011.12.007.
20. Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-na?̈ve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106:1264-1271.
21. Fung J, Lai CL, Young J, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106:1766-1773.
22. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-143.
23. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60:247-254.
24. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56:520-526.
25. Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54:12-18.
26. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice. Hepatology 2011; 53:1854-1863.
27. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34:344-352.
28. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterolgy 2011. doi: 10.1053/j.gastro.2011.12.035.
29. Han GR, Cao MK, Zhao W. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55:1215-1221.
30. Spradling PR, Richardson JT, Buchacz K, et al. Prevalence of chronic hepatitis B virus infection among patients in the HIV outpatient study, 1996-2007. J Viral Hepat 2010; 12:879-886.
31. Piroth L, Pol S, Lacombe K, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53:1006-1012.
32. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-331.
33. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62-72.
34. Singal AK, Fontana RJ. Meta-analysis: oral antiviral agents in adults with decompensated hepatitis B cirrhosis. Aliment Pharmacol Ther 2012; 35:674-689.
35. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatitic decompensation: a randomized, open label study. Hepatology 2011; 54:91-100.
36. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141:1212-1219.